A Phase 1 interventional study of Ketamine (Ketalar) in Pain and Postpartum Depression, sponsored by University of Utah. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University of Utah · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing ketamine in Pain — 8 open to participants now, 10 under way, 5 of them phase 3. Ketamine · Pain.
Among the 95 studies testing ketamine in Pain, this one is the 59th largest by planned enrollment, is one of 3 that started in 2025, is one of 9 in phase 1, and was the 87th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →8 of the 95 studies testing ketamine in Pain are open now, in 2 countries. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 6–17
Keith M Vogt · Sites in United States
Ages 18–59 · Healthy volunteers
Universidad de Antioquia · Sites in Colombia
Ages 18+ · Healthy volunteers
University of Tennessee · Sites in United States
Ages 18+
Antonios Likourezos · Sites in United States
Ages 18–120
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 9 · Phase 3 22 · Phase 4 36
First in 2001; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 70 across the 95 interventional studies. Of the 65 that completed or were terminated, 30 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 95 has an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
33 studies in Pain by University of Utah: 6 open now, 9 under way, 1 of them phase 3. Of 20 finished, 4 (20%) have results posted.
Among the 33 studies in Pain by University of Utah, this one is the 15th largest by planned enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 in phase 1, and was the 32nd registered.
University of Utah’s Pain studies by the year they started, since 2005.
2 of the studies testing ketamine in Pain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07370181Phase 3Assiut UniversityKetamine Irrigation Analgesia in Laparoscopic Cholecystectomy | 2027-02-01 |
| NCT06364540Antonios LikourezosNebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 95 studies testing ketamine in Pain, from their registry updates:
Among University of Utah’s 33 in Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to identify pharmacokinetics of postpartum ketamine infusion. This study will assess ketamine kinetics and metabolism in this setting. Ketamine is expected to exert different kinetics during the physiologic state of post-pregnancy. The goal in conducting this study is to better understand the pharmacokinetics and pharmacodynamics of postpartum ketamine infusion. A secondary goal is to compare these kinetics to reproductive age matched controls and to assess sex differences in ketamine pharmacokinetics.
The peripartum group of this study will receive ketamine after cesarean delivery, while the control group will consist of non-pregnant female subjects and male subjects receiving the same infusion protocol.
A lack of data on new pain treatments in pregnancy puts 1.2 million US women having cesarean delivery (CD) every year at risk for poor pain control, depressed mood, and poor recovery. Evidence of successful post-surgical pain management and rapid reduction of depressive symptoms render ketamine a great candidate for post-CD pain management and potential reduction of postpartum depression (PPD) symptomology. Knowledge gaps in ketamine pharmacokinetics (PK) in the postpartum period limit an informed approach to its use for postpartum analgesia and PPD mitigation strategies. Similarly, knowledge gaps about sex differences in ketamine PK limit understandings about potential heterogeneity of treatment effects. This study aims to better understand the pharmacokinetics and pharmacodynamics of ketamine in postpartum women. Secondarily, it will assess key differences in postpartum ketamine PK compared to non-pregnant female controls. Secondarily it will assess key sex differences in ketamine metabolism between male and female subjects.
Peripartum females undergoing cesarean delivery will receive a ketamine infusion for 12 hours after cord clamping. Samples will be taken to characterize ketamine PK (primary objective). Healthy volunteer control females and males will receive the same ketamine infusion dosing schematic. Comparisons will be made between peripartum females and non-pregnant female controls, and between female and male controls (secondary objectives).
Peripartum Participants:
Inclusion Criteria
Exclusion Criteria
Control Participants
Inclusion Criteria
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Loading dose infusion for 1 hour followed immediately by maintenance dose infusion for 11 hours.
Drug: Ketamine (Ketalar)
Loading dose infusion for 1 hour followed immediately by maintenance dose infusion for 11 hours.
Drug: Ketamine (Ketalar)
Loading Dose: 0.18 mg/kg/hr x 1 hour; Maintenance Dose 0.05 mg/kg/hr x 11 hours
Also known as: 0.18 mg/kg/1hr loading dose Ketamine
Maternal ketamine area under the curve (AUC)
Ketamine area under the plasma concentration-time curve (AUC 0-∞) (AUC, mcg\*min/mL), which reflects the actual body exposure to ketamine after administration of ketamine.
Time frame: 0 to 24 hours from initiation of ketamine infusion
Patient reported acceptability of any reported side effects
Proportion (%) of patient cohort reporting acceptability of ketamine infusion
Time frame: 0 to 24 hours after initiation of ketamine infusion
Pain area under the curve (AUC)
Pain score area under the curve (AUC) where pain scores are measured from 0 (no pain) to 10 (worst imaginable pain), for the duration of epidural analgesia.
Time frame: 0 to 24 hours after initiation of ketamine infusion
Depression scores (Peripartum)
Depression scores as defined by the Edinburgh Postnatal Depression Scale (Peripartum Group), scale 0-30, measured among the peripartum cohort.
Time frame: Baseline to week 12 post-infusion
Depression Scores (control)
Depression scores as defined by the Patient Health Questionnaire (PHQ-9) (Control Group), scale 0-27, measured among the control nonperipartum cohort.
Time frame: Baseline to week 12 post-infusion
Not enrolling at this site.
Plan to share: Yes — Deidentified data will be available for public benefit and knowledge. Items for uploading will include clinical measures, patient reported outcomes, psychometric testing data, sensory testing data, and all PK data. Technical protocols and any other data collected under this project will be shared upon request to allow others to perform secondary analyses.
Supporting information: Study protocol, Clinical study report
Time frame: Beginning with 3 months and ending at 5 years following article publication.
Access criteria: Researchers who propose a methodologically sound proposal may submit said proposals to limkg2@upmc.edu. To gain access to data, requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.
Of 118 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's planned 31 months is above that.
Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
Start moved once since we started tracking on Sep 25, 2026: Mar 2025 → Apr 2025, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketamine